Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Galapagos: Onno van de Stolpe, CEO




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Galapagos: Onno van de Stolpe, CEO
Released on: October 01, 2006. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook.
  • Summary
  • Transcript
  • Participants
  • Company
Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in November 2005, as well as the more recent acquisition of the drug discovery service division of Discovery Partners International. Onno talks in detail about managing Galapagos' strategic osteoarthritis alliance with GlaxoSmithKline and the challenges the company now faces as it expands its operations across the globe.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Onno van de Stolpe founded Galapagos in 1999 while he was Managing Director Genomics at IntroGene (now Crucell). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the US. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Onno started his career as Manager Business Development at MOGEN in Leiden. He received an MSc degree from the Agricultural University in Wageningen.
Galapagos
Galapagos develops drugs to treat bone and joint ailments, amongst other diseases. Its research and development team has partnered with many global pharma companies, including GSK, Merck & Co. and Eli Lilly